Kiromic BioPharma (NASDAQ:KRBP) Stock Price Up 13.9% – Time to Buy?

Kiromic BioPharma, Inc. (NASDAQ:KRBP)’s stock price rose 13.9% during trading on Thursday . The stock traded as high as $1.15 and last traded at $1.15. Approximately 5,000 shares were traded during mid-day trading, a decline of 1% from the average daily volume of 5,047 shares. The stock had previously closed at $1.01.

Kiromic BioPharma Price Performance

The stock has a market capitalization of $1.78 million, a P/E ratio of -0.15 and a beta of 1.95. The company’s 50 day simple moving average is $1.48 and its two-hundred day simple moving average is $2.09.

Kiromic BioPharma (NASDAQ:KRBP) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.74) earnings per share (EPS) for the quarter.

Kiromic BioPharma Company Profile

Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.